News

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

Viz.ai, working in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with the University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

UCSF and ClearPoint Neuro announce partnership to develop an innovative cellular delivery platform from the lab of Dr. Daniel Lim, MD, PhD via an exclusive multi-year licensing agreement. Bringing together UCSF's technology with the ClearPoint system will enable precise and targeted therapeutic...

Foundery Announces Initial Close of Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies

Foundery, a biotechnology venture studio focused on transla6ng immunology discoveries into drug candidates, today announced an initial close of its inaugural fund, Foundery I, LP (“Foundery Fund I”), with total capital commitments and contributed assets as of the closing equal to $29.6 million.

MindRhythm Announces Publication in JAMA Network Open of Novel Headset for Return to Play Decisions in Concussion

Novel, noninvasive, headset detects a newly discovered biometric that allows for objective identification of concussion and recovery. “Concussion is common in sports and returning to play before recovery can cause long-term neurological impairment or permanent brain injury,” said Cathra Halabi, MD...

Philanthropic endowments at universities can offer a way out of biotech’s Valley of Death

"A new idea now taking hold in academia offers the promise of a path out of the Valley of Death: Universities, whose labs are home to so many of these potentially life-changing discoveries, should raise a philanthropic endowment and use the money to fund the work of the scientists to advance their...

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology, a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.

Scalable Care Inc signs landmark license agreement with UCSF to commercialize evidence-based mental health resources

Scalable Care Inc signs an exclusive worldwide licensing agreement with UCSF to commercialize evidence-based digital mental health therapies that help teenagers and young adults manage emotions, cope with trauma, resolve interpersonal conflicts, and learn self-reflection using conversational AI and...

BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data

BeeKeeperAI, Inc., a pioneer in zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), today announced that it has closed $12.1 million in Series A financing. The round was led by Santé Ventures, with participation from the Icahn School of Medicine at...

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to...

MindRhythm Announces First Patient Enrolled in Pivotal Study of Novel Harmony™ Device for Rapid Detection of Stroke

MindRhythm Inc, in partnership with Wayne State University School of Medicine in Detroit, Michigan, today announced that the first patient has been enrolled in the pivotal portion of its HeadPulse for Ischemic Stroke Detection Prehospital Study (EPISODE-VS). EPISODE-VS is designed to validate that...